Telomir Pharmaceuticals, Inc. (TELO) Key Metrics
TELO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $77.3M
- Enterprise value
- $79.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 16.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.30
TELO key metrics, FY2021–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsTELO valuation Price multiples at each fiscal year-end price.
TELO returns How much profit the business earns on the capital it uses.
TELO per-share figures Results divided by the shares outstanding at year-end.
TELO financial health Debt, liquidity and how easily interest is covered.
TELO valuation history
TELO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TELO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TELO price vs earnings per share
TELO key metrics
FY2021–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $44.0M | $189.6M | — | — | — |
| Enterprise value | $37.2M | $188.5M | — | — | — |
| Price / book | 7.4 | 294.9 | — | — | — |
| Earnings yield | −23.7% | −8.7% | — | — | — |
| Free cash flow yield | −8.4% | −2.7% | — | — | — |
| Share price at fiscal year-end | $1.39 | $6.42 | — | — | — |
| Per share | |||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.33 | −$0.56 | −$0.44 | −$0.03 | −$0.00 |
| Operating cash flow per share | −$0.12 | −$0.17 | −$0.13 | −$0.02 | −$0.00 |
| Free cash flow per share | −$0.12 | −$0.17 | −$0.13 | −$0.02 | −$0.00 |
| Cash per share | $0.23 | $0.04 | $0.00 | $0.00 | — |
| Book value per share | $0.19 | $0.02 | $0.12 | −$0.03 | −$0.00 |
| Tangible book value per share | $0.19 | $0.02 | $0.12 | −$0.03 | −$0.00 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.01 | $0.00 | $0.00 | $0.02 | $0.00 |
| Shares outstanding | 31.7M | 29.5M | 29.6M | 29.6M | 29.6M |
| Change in shares outstanding | +7.2% | −0.2% | 0.0% | 0.0% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −317.6% | −810.2% | — | — | — |
| Return on invested capital (ROIC) | — | — | −195.8% | — | −300.9% |
| Return on assets (ROA) | −240.3% | −542.3% | −542.1% | — | −251.1% |
| Return on tangible assets | −141.8% | — | −273.8% | — | −251.1% |
| Financial health | |||||
| Total debt | $473,752 | $93,432 | $101,000 | $581,787 | $119,396 |
| Cash & short-term investments | $7.3M | $1.3M | $1,231 | $1,419 | — |
| Net debt | −$6.8M | −$1.2M | $99,769 | $580,368 | $119,396 |
| Debt / equity | 0.08 | 0.15 | 0.03 | — | — |
| Debt / assets | 0.06 | 0.07 | 0.02 | 11.94 | 2.17 |
| Current ratio | 5.14 | 1.94 | 0.33 | 0.00 | 0.00 |
| Quick ratio | 5.14 | 1.94 | 0.10 | 0.00 | 0.00 |
| Interest coverage | — | -2.8 | -2.4 | — | — |
| Working capital | $5.9M | $643,037 | −$900,339 | −$984,589 | −$138,131 |
| Invested capital | −$899,548 | −$529,662 | $3.5M | −$356,910 | $36,265 |
| Tangible asset value | $5.9M | $643,037 | $3.4M | −$937,278 | −$83,131 |
| Net current asset value | $5.9M | $643,037 | −$900,339 | −$984,589 | −$138,131 |
| Graham net-net per share | $0.19 | $0.02 | −$0.04 | −$0.03 | −$0.00 |
| Capital allocation | |||||
| Capex / depreciation | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | |||||
| Days of inventory on hand | — | — | 28.1 | — | — |
| Days payables outstanding | — | — | 51.5 | — | — |
| Receivables turnover | — | — | 0.00 | — | — |
| Payables turnover | — | — | 7.09 | — | — |
| Inventory turnover | — | — | 13.00 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | $130,000 | — | — |
| Average payables | $562,152 | $647,362 | $555,704 | $211,478 | $18,735 |
| Average inventory | — | — | $303,281 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TELO's annual financial statements (latest annual report filed March 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TELO valuation and financial ratios
Telomir Pharmaceuticals earned a return on equity of −317.6% in fiscal 2025. It ended the year with $0.5 million of debt and $7.3 million in cash and short-term investments, a net cash position of $6.8 million. The share count rose 6.9% from 29.6M to 31.7M over 4 years.
See the TELO income statement, the TELO chart for price history, or the TELO stock overview for the latest quote and news.
TELO key metrics FAQ
What is Telomir Pharmaceuticals's return on equity?
Telomir Pharmaceuticals's return on equity (ROE) was −317.6% in fiscal 2025: net income of -$10.4 million on average shareholders' equity of $3.3 million.
How much debt does Telomir Pharmaceuticals have?
Telomir Pharmaceuticals had total debt of $0.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.08 and more cash than debt.
What is Telomir Pharmaceuticals's free cash flow yield?
Telomir Pharmaceuticals generated -$3.7 million of free cash flow in fiscal 2025, a free cash flow yield of −8.4% on its market value at year-end ($44.0 million).
What is Telomir Pharmaceuticals's current ratio?
Telomir Pharmaceuticals's current ratio was 5.14 at the end of fiscal 2025: current assets were 5.14 times current liabilities.